WHO ICTRP trial
A single-center, randomized, double-blind, placebo-controlled, dose-escalation…
ChiCTR2500101173 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500101173 |
|---|---|
| Public title | A single-center, randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial evaluating the safety, tolerability and pharmacokinetic characteristics of single and multiple transdermal administration of KR230109 in healthy subjects. |
| Scientific title | A single-center, randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial evaluating the safety, tolerability and pharmacokinetic characteristics of single and multiple transdermal administration of KR230109 in healthy subjects. |
| Primary sponsor | Third Xiangya Hospital of Central South University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | Acne vulgaris |
| Interventions | Experimental group:KR230109 Group;placebo group:placebo |
| Registration date | Apr 21, 2025 |
| Target size | Experimental group:40;placebo group:8 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: